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Methylphenidate (MPH) inhibits the reuptake of dopamine and noradrenaline. PET studies withMPH challenge show increased compe-
tition at postsynaptic D2/3-receptors, thus indirectly revealing presynaptic dopamine release. We used [
18F]fluorodopamine
([18F]FDOPA)-PET in conjunction with the inlet–outlet model (IOM) of Kumakura et al. (2007) to investigate acute and long-term
changes in dopamine synthesis capacity and turnover in nigrostriatal fibers of healthy subjects with MPH challenge. Twenty healthy
human females underwent two dynamic [18F]FDOPA PET scans (124 min; slow bolus-injection; arterial blood sampling), with one scan
in untreated baseline condition and the other after MPH administration (0.5 mg/kg, p.o.), in randomized order. Subjects underwent
cognitive testing at each PET session. Time activity curves were obtained for ventral putamen and caudate and were analyzed according
to the IOMtoobtain the regionalnet-uptakeof [18F]FDOPA(K; dopamine synthesis capacity) aswell as the [18F]fluorodopaminewashout
rate (kloss, index of dopamine turnover). MPH substantially decreased kloss in putamen (22%; p 0.003). In the reversed treatment
order group (MPH/no drug), K was increased by 18% at no drug follow-up. The magnitude of K at the no drug baseline correlated with
cognitive parameters. Furthermore, individual kloss changes correlatedwith altered cognitive performanceunderMPH. [
18F]FDOPAPET
in combination with the IOM detects an MPH-evoked decrease in striatal dopamine turnover, in accordance with the known acute
pharmacodynamics of MPH. Furthermore, the scan-ordering effect on K suggested that a single MPH challenge persistently increased
striatal dopamine synthesis capacity. Attenuation of dopamine turnover byMPH is linked to enhanced cognitive performance in healthy
females.
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Introduction
Methylphenidate (MPH) facilitates dopaminergic transmission
by inhibiting the dopamine reuptake transporter (DAT). In clin-
ical practice, MPH is treatment of choice in attention deficit/
hyperactivity disorder (ADHD). Because of its straightforward
pharmacodynamic mechanism, MPH has also been used as a
challenge in PET investigations inducing increased competition
between D2/3-receptor ligands and endogenous dopamine
(Volkow et al., 1994; Rosa-Neto et al., 2005). This MPH-induced
reduction of the ligand binding potential, however, is a surrogate
parameter of the changes in dopamine concentrations and is con-
founded by some biological processes, such as receptor internal-
ization (Skinbjerg et al., 2010). The present approach using
[18F]fluorodopamine ([18F]FDOPA) does not target the estima-
tion of dopamine release but mimics the presynaptic synthesis
pathway of dopamine. Given that the primary application of
MPH (ADHD) is claimed to be characterized by presynaptic dis-
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turbances (e.g., Ernst et al., 1998; Volkow et al., 2007; Ludolph et
al., 2008), the evaluation of MPH effects by a predominantly
presynaptic tracer appears to be reasonable.
Until now, [18F]FDOPA PET was not used for the evaluation
ofMPHeffects; it traces the dopamine synthesis capacity in brain,
which appears to be less vulnerable for environmental and phar-
macological influences (Gru¨nder et al., 2003; Vernaleken et al.,
2013). However, most quantitative FDOPA PET studies assume
irreversible trapping of [18F]FDOPA, whereas the inlet–outlet
model (IOM) of Kumakura et al. (2007) yields the net clearance
of [18F]FDOPA to brain (K; ml  g1min1), accommodating
the delayed washout of decarboxylated and deaminated metabo-
lites, which is explicitly defined by the rate constant kloss (min).
Thus, the [18F]FDOPA IOM can reveal acute changes in the do-
pamine dynamics.
Using thismodel, the present investigation intends tomonitor
the acute and delayed effects of MPH on dopamine turnover
(kloss) and dopamine synthesis capacity (K) as well as respective
correlations with cognitive changes. Because DAT inhibition will
reduce the rate of dopamine reuptake into the cytosolic compart-
ment where it would be exposed tomonoamine oxidase (Nielsen
et al., 1983; Zetterstro¨m et al., 1988), we hypothesize that the
magnitude of kloss will be reduced. We furthermore expect that
changes in kloss correlate with enhancement in cognition under
MPH treatment.
Therefore, two [18F]FDOPA PET scans (A: untreated control
condition; B: scan after MPH challenge) were conducted in healthy
subjects. Because long-term effects of psychostimulants on dopa-
mine transmission and sensitization are known (Calipari et al.,
2014), this study was conducted with two treatment order groups
(no drug/MPH and MPH/no drug) to obtain possible regulatory
effects of a singleMPH dose on presynaptic dopaminemetabolism.
Materials andMethods
Subjects. Twenty healthy, nonsmoking female subjects 21–28 years of age
(mean  SD, 24.0  1.9 years) were included in the study, which had
been approved by the Research and Ethics Committees of the University
Hospital of RWTH Aachen University. All subjects provided written
informed consent. Exclusion criteria for the volunteers included current
neurological, psychiatric, or systemic disease, pregnancy (13 of 20 sub-
jects were using oral contraceptives), and current use of drugs affecting
the CNS. All 20 subjects are a small subgroup of a large neurogenetic
study group of women (n 200) not including molecular imaging tech-
niques (Schabram et al., 2013). The cohort is well characterized in respect
to demographics, and by intention highly homogeneous in age, gender,
and education. Men were not included to reduce heterogeneity and to
improve the statistical power for main effects. The 20 PET subjects were
randomly distributed into two treatment groups (usual or reversed order
of baseline/MPH PET scans). To optimize statistical power for the two
main hypotheses, the groups were asymmetrically distributed, with 14
receiving first the unmedicated control scan, followed by the MPH con-
dition, and six being scanned in reversed order.
Neuropsychology. To investigate the prefrontal cognitive capacities of
the participants in the two scanning conditions, we administered the
Trail Making Test (TMT-AB) of executive functioning (Reitan, 1955),
Stroop test (Ba¨umler, 1985), d2-concentration test of attention (Brick-
enkamp, 2002), and degraded stimulus continuous performance task
(dsCPT) for measuring attention, in which subjects need to react on
either a degraded or contoured target stimulus (Schabram et al., 2013).
Following upon Kathmann et al. (1996), dsCPT was analyzed according
to the signal detection theory (SDT) (Peterson et al., 1954). The test
parameters for hits, missed, false alarms, and correct rejections were
entered into analysis using BayesSDT software package for MATLAB
(Lee, 2008) to obtain the following primary outcome variables: discrim-
inability (sensitivity index, d) and decision-bias (). This bias indicates
either a more liberal (negative values) or a more conservative (positive
values) trend toward accepting a stimulus as a target and is independent
of the overall performance. The first part (d2 test and TMT) of neuro-
psychological testing was performed1 h before PET scan, whereas for
technical reasons the dsCPT was performed after scan.
MPHchallenge. Participants receivedMPH(Ritalin,Novartis Pharma-
ceuticals) at a dose of 0.5 mg/kg adjusted for body weight either at first
(n 6) or second PET scan (n 14). Based upon pharmacokinetics of
oral MPH, the drug was administered 2 h before tracer injection
(Markowitz et al., 2003). Because of legal and institutional restrictions, it
was not possible to include a placebo drug formulation in the study
design. The medication condition was therefore not blinded.
PET scanning and plasma sampling procedure. Before each PET scan, a
pregnancy test was performed. [ 18F]FDOPA scans were recorded with
the Siemens ECAT HR whole-body PET, which has a field of view of
16.2 cm in 47 planes, an interplane spacing of 3.375 mm, and an axial
resolution of 5.4 mm FWHM. Decarboxylation of [ 18F]FDOPA in pe-
ripheral tissueswas inhibited by oral administration of carbidopa (Merck
Sharp&Dome, 2mg/kg bodyweight), ofwhich two-thirdswere given 1 h
after and one-third before start of the emission recording. After a brief
attenuation scan, a dynamic emission sequence lasting 124 min began
upon intravenous injection of [ 18F]FDOPA at a dose of 226  21 MBq
(range, 166–263 MBq) as a slow bolus. Frame length increased progres-
sively according to the following schedule: 3 20 s; 3 1min, 3 2min,
3 3min, 15 5min, 3 10min interval (Gru¨nder et al., 2003). Blood
was automatically drawn from a radial arterial catheter (first 10 min),
and the radioactivity concentration measured at 1 s intervals with an
online -counter (Allogg ABSS V3) cross-calibrated to the tomograph.
Subsequently, a series of 15 arterial blood samples are drawn manually,
and their radioactivity concentrations measured using a well counter
(PerkinElmer Wizzard2 gamma-counter). The fractions of untrans-
formed [18F]FDOPA and its major plasma metabolite 3-O-methyl-
[ 18F]-fluorodopa ([ 18F]OMFD) were measured by reverse-phase high
performance liquid chromatography (Cumming et al., 1993) in plasma
extracts prepared from arterial blood samples. The continuous plasma
fractions of [ 18F]FDOPA andOMFDwere calculated by interpolation of
biexponential functions fitted to the measured fractions, and the two
input functions calculated by multiplication with the total blood curve
(Gillings et al., 2001).
PET data analysis. Emission images were reconstructed by filtered
back projection with a 4 mmHanning filter. The dynamic sequence was
frame-wise corrected for head motion, using an interframe rigid-body
transformation implemented in PMOD (Version 3.4, PMOD Technol-
ogy). For spatial normalization, the summed images were first coregis-
tered to the individual MR (1.5T MRT Scanner; Philips Gyroscan NT;
PhilipsMedical Systems), and theMR-registered sequence was then nor-
malized to the ICBM-452 template (Mazziotta et al., 2001) using PMOD
(Brain Normalization II routine), and a 12 parameter rigid-body trans-
formation. Decay-corrected time activity curves (TACs) were then cal-
culated for a set of volume of interest templates, including cerebellum,
and left and right ventral caudate nucleus and ventral putamen. For one
participant with contraindications against MR tomography, PET images
were registered to a normalized [ 18F]FDOPA-template.
[18F]FDOPA kinetics. Most brain [ 18F]FDOPA studies are quantified
by linear graphical analysis relative to the arterial [ 18F]FDOPA input, or
a reference tissue surrogate. With PET recordings of 45–60 min, graph-
ical analysis yields an index of [ 18F]FDOPA utilization that assumes
irreversible trapping, thus ignoring the rapid formation of deaminated
[18F]FDOPA metabolites in living striatum, and their diffusion from
brain (Cumming et al., 1993). Because this metabolic process entails
useful information about the turnover of the neurotransmitter pool, we
elected to use the reversible IOM (Kumakura et al., 2007) for kinetic
analysis of the regional TACs. The IOM is based on principles similar to
those of the reversible tracer model of Sossi et al. (2001), as also used by
Cumming et al. (2001); both approaches yield outcome parameters for
the net blood–brain clearance of [ 18F]FDOPA, a fractional rate constant
for the diffusion from brain of deaminated [18F]FDOPA metabolites,
and also a distribution volume,which reflects dopamine storage capacity.
The approach of Sossi et al. (2001) necessarily entails PET acquisition
times of 4 h, whereas the presents IOM applies for recordings of only 2 h
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because of amore accurate subtraction of brain radioactivity arising from
the peripheralmetaboliteOMFD. The IOMentails a three-step approach
in which a constrained one tissue compartment model is first used to
calculate the TAC for plasma-derived [18F]OMFD in cerebellum, which
contains negligible DOPA-decarboxylase activity. Here the permeability
ratio (q) for the two substances arising from blood (OMFD/FDOPA) is a
fixed parameter (Gjedde et al., 1991; Huang et al., 1991), set to a magni-
tude of 1.5, which is themean of the limited number of explicit measure-
ments (Cumming and Gjedde, 1998). Assuming, like all [ 18F]FDOPA
models, homogeneous distribution of [ 18F]OMFD throughout brain,
the curve calculated in cerebellum is then subtracted from the entire 4D
PET recording, to isolate the brain contents of [18F]FDOPA, [18F]FDOPA,
and its deaminatedmetabolites, which freely diffuse from brain. The first
20 min are excluded from the IOM analysis because of the need for an
equilibrium for [ 18F]FDOPA in brain (Kumakura et al., 2007). Finally,
themultilinear formof the IOM is applied to the “cleaned” brainTACs to
calculate the steady-state parameters alluded to above: (1) the net blood–
brain clearance of [ 18F]FDOPA (K, ml hg1 min1), which is an index
of dopamine synthesis capacity; (2) the washout rate for [ 18F]FDOPA
together with its deaminatedmetabolites (kloss; min
1), which is compa-
rable with the biochemical assays of dopamine turnover; and (3) the
steady-state distribution volume of [ 18F]FDOPA together with its decar-
boxylated metabolites (Vd; ml/g), which is an index of dopamine storage
capacity comparable with the effective distribution volume (EDV;
ml  g1) defined by Sossi et al. (2001).
Statistical analyses. Wilcoxon’s rank order tests for paired samples
were conducted to investigate effects of MPH on cognition and PET
parameters (K, kloss, and Vd). The baseline versus MPH condition differ-
ences (percentage of the change) were calculated as ([no drugMPH]/no
drug 100). 	 parameters were calculated for K, kloss, and the cognitive
measures (MPHcondition subtracted by drug-free condition) indicating
the percentage of change. To examine the order of treatment effect, an
independent t test was conducted for	-K and	-kloss. To justify a deeper
investigation for treatment order effect, a prescreening threshold of p

0.2 was applied for the decision to include parameters in the repeated-
measures ANOVA (i.e.,K and treatment order). Furthermore, Spearman
correlations between baseline PET parameters and baseline neuropsy-
chology scores, 	neuropsychology scores, 	-K and 	-kloss were calcu-
lated. To correct formultiple testing, a Bonferroni correction at 0.05,
calculated by the Dubey/Armitage-Pamar  boundary (Sankoh et al.,
1997) was used. This correction includes the correlation among the
regions.
Results
All 20 subjects successfully completed the two PET scans. In two
subjects, neuropsychological testing (d2 test, TMT-AB) was
lost because of technical problems. Mean IQ was 110.43 12.13
(SD) (Table 1). Themean (SD) specific activity of fluorine-18was
9.4  1.9 MBq/mol (range 5.7–13.6 MBq/mol), indicating a
total injectedmass of4 pmol; therewere no significant differences
in specific activitybetweenthe twoPETscans (T1.327,p0.231).
Themean (SD) dose ofMPHwas 33.0 6.4mg (range 20–50mg).
Therewas no group differences in the stage ofmenstrual cycle at the
scanning day, nor any main effect of cycle or oral contraceptive use
on any [18F]FDOPA PET parameter at baseline.
Table 1. Cognitive performance scores
No drug N MPH condition N Change (	) % Change Z p
IQ 110.4 12.1 14
TMT-A (s) 17.5 4.5 19 16.4 3.5 20 1.17 6.67 1.187 0.235
TMT-B (s) 34.1 9.2 19 33.5 9.8 20 0.62 1.82 0.523 0.601
Stroop interference 30.0 8.1 20 29.2 8.1 20 0.74 2.47 0.709 0.478
Decision bias 0.64 0.90 19 0.34 0.088 20 0.3 53.13 1.933 0.053
Sensitivity d 2.00 0.90 19 2.23 0.93 20 0.23 11.50 1.023 0.306
dsCPT hits 6.74 2.02 19 7.20 1.79 20 0.46 6.82 0.742 0.458
d2 concentration performance 246.0 30.9 19 260.8 28.1 20 14.8 6.02 2.865 0.004*
*p
 0.05.
Table 2. Effect of MPH challenge on 18FFDOPA PET kinetic parameters
CTR, no drug condition MPH, methylphenidate condition
%Change:
MPH-CTR Z pMean SD N Mean SD N
kloss
CN right 0.0036 0.0015 19 0.0028 0.0009 20 22% 1.972 0.048*
CN left 0.0035 0.0015 20 0.0031 0.0011 20 10% 1.157 0.247
CN bilateral 0.0036 0.0014 19 0.0030 0.0009 20 17% 1.932 0.053
PUT right 0.0037 0.0011 19 0.0031 0.0011 20 15% 2.093 0.036*
PUT left 0.0037 0.0014 20 0.0029 0.0008 20 22% 2.949 0.003**
PUT bilateral 0.0038 0.0012 19 0.0030 0.0008 20 20% 2.656 0.007**
K
CN right 0.0198 0.004 19 0.0196 0.003 20 1% 0.322 0.748
CN left 0.0201 0.005 20 0.0198 0.003 20 1% 0.299 0.765
CN bilateral 0.0200 0.005 19 0.0197 0.003 20 2% 0.040 0.968
PUT right 0.0226 0.005 19 0.0224 0.004 20 1% 0.080 0.936
PUT left 0.0224 0.005 20 0.0216 0.003 20 4% 0.672 0.502
PUT bilateral 0.0226 0.005 19 0.0220 0.003 20 3% 0.161 0.872
Vd
CN right 7.05 3.37 19 7.73 2.36 20 10% 1.288 0.198
CN left 7.41 3.25 20 7.41 3.25 20 0% 0.560 0.575
CN bilateral 6.96 3.28 19 7.57 2.74 20 9% 1.046 0.295
PUT right 6.94 2.78 19 8.19 2.85 20 18% 1.569 0.117
PUT left 7.42 3.94 20 8.30 2.82 20 12% 1.680 0.093
PUT bilateral 7.14 3.23 19 8.24 2.60 20 16% 2.012 0.044*
CTR, No drug condition; CN, caudate nucleus; PUT, putamen; MPH, methylphenidate condition.
*p
 0.05; **p
 0.01.
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Neuropsychological measurements
The results of the neuropsychological tests are displayed in Table
1.MPH increased concentration performance parameter (CP) in
the d2 task (control condition: 245.95 30.86, MPH: 260.75
28.06 (mean  SD); 6.0%, Z  2.87, p  0.004). However,
there was no effect of MPH on TMT or dsCPT parameters.
PET parameters baseline
The mean (SD) magnitudes of [18F]FDOPA IOM parameters
kloss,K, andVd in ventral caudate nucleus and in ventral putamen
are reported in Table 2. The baseline kloss was 0.0036  0.0014
min1 in the bilateral caudate nucleus and 0.0038  0.0012
min1 in the bilateral putamen. There were no significant side
differences. BaselineKwas 0.0200 0.005ml  g1  min1 in
the bilateral caudate nucleus and 0.0226  0.005
ml  g1  min1 in the bilateral putamen.Mean (SD) baseline
Vdwas 6.96 3.28 ml  g
1 in the bilateral caudate nucleus and
7.14  3.23 ml  g1 in the bilateral putamen. In one partici-
pant, two ROIs (caudate right and putamen right) were excluded
from consideration because of poor fitting outcome.
Effect of MPH on PET parameters
In the MPH challenge condition, mean (SD) kloss was 0.003
0.0009 min1 in bilateral caudate nucleus and 0.003  0.0008
min1 in bilateral putamen. Thus, MPH reduced kloss by 22% in
right caudate nucleus (Z1.97, p 0.048, n 19), 22% (Z
2.95, p 0.003, n 20) in left putamen, and 15% (Z2.09,
p 0.036, n 19) in right putamen (Table 2; Fig. 1a).Mean (SD)
K was 0.0197  0.003 ml  g1  min1 for bilateral caudate
nucleus and 0.0220  0.003 ml  g1  min1 for bilateral puta-
men; there were no significant effects of MPH on K (n 20).
Order of treatment effect
To test whether the order of the drug treatment had an effect on
the PET parameters, we first performed an independent-sample t
test; this showed that	K in bilateral caudate nucleus and bilateral
putamen differed between groups (caudate: T 1.90, p 0.075
n 19; putamen: t 2.90, p0.010, n 19). The	-kloss param-
eter showed no general effect of treatment order, except in left
putamen (T 2.589, p 0.019, n 20). Because of these results,
we performed repeated-measures ANOVAs, including K as a
within-subjects variable and “order of treatment” as a between-
subject variable. The tests revealed nomain effect ofK but amain
effect of order of treatment and an interaction effect in bilateral
putamen (F  8.426, p  0.01*; K*order of treatment; see also
Table 3). Bilateral caudate nucleus showed a trend in order of treat-
menteffect.Theposthocanalyses revealed that, in those subjectswith
reversed order of drug application (MPH scan first), baselineK esti-
mates in bilateral putamen were 24% higher than for the conven-
tional order group (Z2.368, p 0.018, n 19), with a trend in
Figure 1. a, Reductions in [ 18F]FDOPA kloss in bilateral putamen after MPH challenge ( p 0.007, n 19, complete sample). b, Correlation between time at Trail Making Test B and no drug
[ 18F]FDOPAK in left putamen ( p0.029,n14, conventional order group). c, Correlationbetweennodrug [ 18F]FDOPAKand concentrationperformanceparameter (CP) in right and left putamen
(PUT) (right: p 0.039, n 12; left p 0.007, n 13, conventional order group). d, Correlation between change in [ 18F]FDOPA kloss and change in concentration performance underMPH ( p
0.040, n 12, conventional order group).
Table 3. ANOVA for 18FFDOPA K in PUT and CN
df F p
CN
18FFDOPA K 1 0.45 0.511
Treatment order 1 3.098 0.095
K TO 1 4.325 0.052
PUT
18FFDOPA K 1 2.291 0.147
Treatment order 1 6.042 0.024*
K TO 1 8.122 0.011*
PUT, Putamen; CN, caudate nucleus; TO, treatment order.
*p
 0.05.
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bilateral caudate nucleus (Z1.842, p0.072, n 19,Wilcoxon
test). Insofar as this may indicate a carryover effect 2 weeks after
MPH on [18F]FDOPA kinetics, we analyzed post hoc differences for
both groups (Table 4). The results indicate that the increase was K
only significant in the reversed-order group.
Relationships between cognitive performance and baseline K
Because of the order of treatment effect, correlations between K
and neuropsychological measures were conducted only within
the conventional order group (n  14). We found that baseline
magnitude of K in left putamen correlated negatively with base-
line TMT-B: the lower K, the better the performance (Fig. 1b)
(TMT-B ismeasured in seconds, such that briefer duration of the
test indicated better workingmemory). Furthermore, there was a
negative correlation between CP (d2 test) scores andK in left and
right putamen (Table 5; Fig. 1c).
Correlations with change in kloss and change in
neuropsychological measurements
There was a strong correlation between 	-kloss in bilateral puta-
men and the improvement in CP under MPH (r  0.599, p 
0.040, n  12, Spearman; Fig. 1d). Furthermore, 	-kloss in right
putamen correlated negatively with the change in decision bias
(	-) within the conventional order group (r  0.630, p 
0.028, n 12, Spearman).
Discussion
Using [18F]FDOPA PET in conjunction with the IOM approach
for estimation of the dopamine turnover, the present study was
designed to quantify direct effects of acute MPH on nigrostriatal
dopamine metabolism in healthy females and to link these phar-
macodynamic effects to individual cognitive performance
changes. We found the expected decrease of kloss in the MPH
condition. Most likely, kloss is decreased because of particular
action of MPH as a reuptake inhibitor, which decreases the reen-
try of released dopamine into the intracellular substrate pool for
monoamine oxidase. Thus, under MPH, the oxidative deamina-
tion of released dopamine to the diffusiblemetabolite DOPACby
monoamine oxidase is largely disabled (Nielsen et al., 1983;
Zetterstro¨m et al., 1988). Furthermore, autoreceptor-mediated
feedback reduces the formation of diffusible dopamine metabo-
lites. Nonetheless, the magnitude of K was unaffected by acute
MPH treatment, such that the observed changes of volume of
distribution (Vd) are mostly driven by kloss. Baseline parameters
for attention performance (CP [d2 test] and TMT-B) correlated
with baseline [18F]FDOPA K in putamen; similar results for
other cognitive parameters are found in previous studies (Ver-
naleken et al., 2007, 2008). We also detected significant correla-
tions between [18F]FDOPA 	-kloss and change of cognitive
performance parameters evoked byMPH: in particular, the indi-
vidual change of the decision bias (	) and the extent of kloss
reduction correlated positively. Furthermore, 	CP correlated
strongly with	kloss, indicatingmore pronounced attentional im-
provement in subjects with the greatest pharmacodynamic effect
of MPH. Interestingly, our randomized study design revealed a
strong PET scan-ordering effect, such that there was an apparent
increase in drug-free [18F]FDOPA K (the dopamine synthesis
capacity) persisting at 2weeks after a single,moderateMPHdose.
It is well known that MPH inhibits the plasma membrane
catecholamine transporters, causing an increase of intrasynaptic
dopamine and noradrenaline concentrations. Volkow et al.
(1998, 1999) described DAT occupancy of up to 74% in human
subjects treated with MPH. Microdialysis studies have shown
doubling of the interstitial dopamine concentration in rat stria-
tum after oral MPH administration (Gerasimov et al., 2000; Ber-
ridge et al., 2006). PreviousD2/3-receptor ligand PET studies have
shown availability decreases in healthy subjects ranging from 6%
to 27%withMPH challenge (Volkow et al., 1994; Udo de Haes et
al., 2005; Del Campo et al., 2011). The construct validity of the
competition paradigm, however, has some caveats because re-
sults depend on which D2/3 ligand is used (Gjedde and Wong,
1987;Morris andYoder, 2007) and an imperfect relation between
interstitial dopamine changes and the time course of alterations
in receptor availability seen by PET exists (Laruelle et al., 1997;
Houston et al., 2004). This discrepancymay be related to receptor
internalization and affinity states induced by dopamine agonists.
Studies showed internalization effects for amphetamine, dopa-
mine, and dopamine agonists (Bartlett et al., 2005; Skinbjerg et al.,
2010).Given thesevagaries,weproposed that the [18F]FDOPAIOM
should provide a more interpretable assay of the pharmacody-
namic effects of a psychostimulant challenge. Indeed, the per-
centage change of kloss exceeded that of the D2/3-receptor
availability seen in many MPH challenge studies.
Table 4. Treatment order effect: post hoc analyses within group differences in bilateral 18FFDOPA K
Group 18FFDOPA K No drug SD N MPH SD N Change (	) % Change Z p
CTR-MPH CN 0.0204 0.0031 14 0.0218 0.0038 14 0.0014 7% 1.083 0.279
PUT 0.0186 0.0035 14 0.0195 0.0035 14 0.0009 5% 1.642 0.101
MPH-CTR CN 0.0273 0.0063 6 0.0224 0.0030 6 0.0049 18% 1.782 0.075
PUT 0.0230 0.0056 6 0.0200 0.0018 6 0.0030 13% 1.992 0.046*
CTR, No drug condition; CN, caudate nucleus; PUT, putamen; MPH, methylphenidate condition.
*p
 0.05.
Table 5. Correlations between neuropsychological parameters and 18FFDOPA K in bilateral CN and PUT
CN PUT
Bilateral p Right p Left p Bilateral p Right p Left p
TMT-A 0.093 NS 0.082 NS 0.258 NS 0.14 NS 0.21 NS 0.027 NS
TMT-B 0.495 0.086 0.599 0.031* 0.154 NS 0.545 0.067 0.497 NS 0.604 0.029*
d2 CP 0.492 0.087 0.583 0.036* 0.294 NS 0.75 0.005** 0.701 0.011 0.707 0.007**
Decision bias 0.214 NS 0.192 NS 0.154 NS 0.056 NS 0.007 NS 0.016 NS
Discriminability d 0.027 NS 0.044 NS 0.099 NS 0.259 NS 0.273 NS 0.236 NS
CN, Caudate nucleus; PUT, putamen; NS, not significant.
*p
 0.05; **p
 0.01.
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The parameter kloss reflects the composite of partitioning of
[18F]FDOPA between cytosolic and vesicular compartments, re-
lease and reuptake, subsequent exposure to monoamine oxidase,
and diffusion of deaminated metabolites from brain (Deep et al.,
1997). Despite this complexity, we have shown that the klossmag-
nitude depicts the steady-state fractional rate constant for dopa-
mine turnover (Deep et al., 1997). As such, our observations of a
positive association between decrease of kloss and MPH-related
modulations of cognitive performance link the pharmacody-
namic effect of MPH on dopamine metabolism; the more
pronounced the decrease in kloss, the less improvement in concen-
tration performance was observed. Analogously, a previous
[18F]FDOPA IOM study showed that individual changes in kloss
following haloperidol challenge likewise correlate with cognitive
changes (Vernaleken et al., 2008). In the present study, MPH did
not evoke cognitive improvement in every case; we suppose that
many in our cohort were high achievers with normal IQ, and
already in a state of optimal dopamine balance, which could not
be improved by MPH challenge. Using the SDT analyses, we
detected another important association consistent with procog-
nitive and attention effects of MPH in ADHD patients; partici-
pants who manifested the strongest impact of MPH in reducing
kloss also showed the strongest shift to a more conservative deci-
sion bias. The decision bias provides a measure of how liberal or
conservative the decisions were, regardless of overall perfor-
mance. These findings might be relevant for several psychiatric
disorders that include cognitive disabilities (van Beilen et al.,
2008; Jokinen et al., 2013; Kumakura et al., 2013).
Thewidespread clinical use of psychostimulants inADHDhas
raised concerns with respect to long-term treatment effects. Be-
havioral sensitization to amphetamine is well known in rodent
studies (Robinson et al., 1982), and previous MPH treatment
evokes persistent changes in interstitial dopamine (Calipari et al.,
2013, 2014) and NMDA receptors in rat brain (Urban et al.,
2013). A humanPET study revealed potentiation of reductions in
amphetamine-evokedD2/3-receptor availability somemonths af-
ter the previous dose of amphetamine, indicating persistent sen-
sitization (Boileau et al., 2006). Based on these results, our study
design included a subgroupwith a reversed order of the drug-free
and pharmacological challenge [18F]FDOPA PET scans. We did
see an order effect on the magnitude of K; MPH treatment 2
weeks before the scan significantly (18%) increased striatal do-
pamine synthesis capacity. This presynaptic change might have
arisen through feedback regulation of dopamine autoreceptors,
which could likewise be a factor in the amphetamine sensitization
reported by Boileau et al. (2006). Verification of the presynaptic
potentiation would require prospective [18F]FDOPA studies
with repeated psychostimulant challenge. Ernst et al. (1999)
found that ADHDpatients had increased [18F]FDOPA uptake in
midbrain comparedwith healthy subjects, despite being drug free
for several weeks. Present findings suggest that this, too,may have
reflected a carryover effect rather than an ADHD trait per se. Our
main endpoint in the present study, kloss, obviously is a more
volatile parameter, being related to present state of dopamine
turnover. Consistent with this conception, we saw no evidence
for a carryover in the magnitude of kloss. If further studies repli-
cate our finding of persistently increased dopamine synthesis ca-
pacity followingMPH, it will become an issue whether this effect
contributes to the beneficial clinical effects in ADHD, which are
usually attributed to the acute increase of dopamine levels.
Some limitations of the present study should be noted. In
general, the complex nature of [18F]FDOPAmetabolism in brain
(Cumming et al., 1987) hampers the interpretation of our findings.
The IOM, which accommodates the reversibility of [18F]FDOPA
trapping, is necessarily a simplification of the biological complex-
ity of dopaminemetabolism. As noted above, ourmain endpoint
kloss is explicable as an index of dopamine turnover, traced by the
elimination of the [18F]FDOPA pool formed in striatum, such
that a reduction of kloss reflects a decline in turnover. Our previ-
ous results confirm the (patho)physiological relevance of dis-
turbed kloss in psychiatric and neurological disorders (Kumakura
et al., 2007). In contrast, the [18F]FDOPAparameterK represents
the capacity to use (exogenous) [18F]FDOPA in brain, which is
hardly subject to regulation upon acute MPH challenge. We pre-
viously reported changes in [18F]FDOPA K upon treatment for
3 d with a D2/3-anatgonist (Vernaleken et al., 2008), whereas
short-term antipsychotic treatment had no effect on correspond-
ing m-tyrosine PET findings (Mamo et al., 2004; Vernaleken et
al., 2006). Our design deliberately entailed a test of order effect on
[18F]FDOPA kinetics, which revealed kloss to be robust to this
factor, whereas Kwas increased by previous MPH exposure. Our
subjects did not otherwise report any previous use of psycho-
stimulants, so we feel confident in our observation of a main
effect of MPH challenge on kloss. In clinical [
18F]FDOPA studies
of ADHD patients, drug treatment history is very likely to be
relevant, given that K was strongly affected by previous one-time
MPH use. Nevertheless, the unequal group sizes call for caution
in the interpretation of this finding. The group with the reversed
treatment order (n 6)was smaller than the groupwith standard
scanning order (n 14). This was, by design, to provide suffi-
cient power for testing the main hypotheses concerning cor-
relations between PET and cognitive changes. Also notably,
the test–retest variability is 10% for conventional reference tis-
sue [18F]FDOPA PET (Egerton et al., 2010); the corresponding
covariance remains to be established for the IOMmethod. Given
that a possibly higher variance in the outcome parameters of the
IOM might exist, which would impair the test–retest reliability,
from a statistical point of view, this would not relativize the fact
that, based on the present observations, the probability to reject a
possible true null hypothesis is 
5% (risk of false positive as
depicted by  0.05). Lower test–retest reliability, however, de-
pends on higher necessary effects to contrast against the higher
level of noise in the data.
Notes
Supplementalmaterial for this article is available at http://www.ukaachen.de/
fileadmin/files/klinik-psychiatrie/Download_Personen/The_reversible_
Inlet-Outlet_Model.pdf.Detailed description of the reversible Inlet/Out-
let Model. Giving a more complete overview and a better understanding
of the kinetic model which is used in this manuscript. This material has
not been peer reviewed.
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